Cipla Limited has signaled filing traction for injectable peptides, a key component of its scale-up strategy in the US, alongside expectations of business momentum with a string of high value complex launches slated for the second half of fiscal year 2023.
Partnering Interest For Monkeypox
Cipla has indicated its interest in partnering opportunities for drugs to address the spread of monkeypox and is also looking at potential repurposing options.
The Indian firm is also considering partnering opportunities for monkeypox (see side box).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?